tradingkey.logo

Xtant Medical Holdings Inc

XTNT
0.770USD
0.000
交易中 美东报价延迟15分钟
107.80M总市值
59.51市盈率 TTM

Xtant Medical Holdings Inc

0.770
0.000

关于 Xtant Medical Holdings Inc 公司

Xtant Medical Holdings, Inc. is a global medical technology company. The Company is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, OsteoVive, OsteoFactor, line of 3Demin products, as well as other allografts. It offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical products, Thoracolumbar products, Sacroiliac Joint products, Interbody products and Interlaminar Stabilization products.

Xtant Medical Holdings Inc简介

公司代码XTNT
公司名称Xtant Medical Holdings Inc
上市日期Jun 30, 2010
CEOBrowne (Sean E)
员工数量217
证券类型Ordinary Share
年结日Jun 30
公司地址664 Cruiser Lane
城市BELGRADE
上市交易所NASDAQ OMX – NASDAQ Basic Amex
国家United States of America
邮编59714
电话14063880480
网址https://xtantmedical.com/
公司代码XTNT
上市日期Jun 30, 2010
CEOBrowne (Sean E)

Xtant Medical Holdings Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Stavros G. Vizirgianakis
Mr. Stavros G. Vizirgianakis
Independent Chairman of the Board
Independent Chairman of the Board
7.52M
+7.95%
Mr. John K. Bakewell
Mr. John K. Bakewell
Independent Director
Independent Director
1.07M
+41.87%
Mr. Robert E. Mcnamara
Mr. Robert E. Mcnamara
Independent Director
Independent Director
591.99K
-2.79%
Mr. Scott C. Neils
Mr. Scott C. Neils
Chief Financial Officer
Chief Financial Officer
575.01K
+84.46%
Mr. Abhinav (Abi) Jain
Mr. Abhinav (Abi) Jain
Director
Director
158.23K
--
Ms. Lori D. Mitchell-Keller
Ms. Lori D. Mitchell-Keller
Independent Director
Independent Director
--
--
Mr. Tyler P. Lipschultz
Mr. Tyler P. Lipschultz
Director
Director
--
--
Mr. Sean E. Browne
Mr. Sean E. Browne
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Mark A. Schallenberger
Mr. Mark A. Schallenberger
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Jonn R. Beeson
Mr. Jonn R. Beeson
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Stavros G. Vizirgianakis
Mr. Stavros G. Vizirgianakis
Independent Chairman of the Board
Independent Chairman of the Board
7.52M
+7.95%
Mr. John K. Bakewell
Mr. John K. Bakewell
Independent Director
Independent Director
1.07M
+41.87%
Mr. Robert E. Mcnamara
Mr. Robert E. Mcnamara
Independent Director
Independent Director
591.99K
-2.79%
Mr. Scott C. Neils
Mr. Scott C. Neils
Chief Financial Officer
Chief Financial Officer
575.01K
+84.46%
Mr. Abhinav (Abi) Jain
Mr. Abhinav (Abi) Jain
Director
Director
158.23K
--
Ms. Lori D. Mitchell-Keller
Ms. Lori D. Mitchell-Keller
Independent Director
Independent Director
--
--

收入明细

单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Orthobiologics
19.37M
54.70%
Spinal implant
11.07M
31.25%
License revenue
4.97M
14.05%
地区USD
名称
营收
占比
United States
32.13M
90.74%
Rest of World
3.28M
9.26%
业务
地区
业务USD
名称
营收
占比
Orthobiologics
19.37M
54.70%
Spinal implant
11.07M
31.25%
License revenue
4.97M
14.05%

股东统计

更新时间: 11月22日 周六
更新时间: 11月22日 周六
持股股东
股东类型
持股股东
持股股东
占比
Nantahala Capital Management, LLC
48.85%
Lytton (Laurence W)
6.76%
Vizirgianakis (Stavros G)
5.37%
AWM Investment Company, Inc.
4.71%
The Vanguard Group, Inc.
1.68%
其他
32.63%
持股股东
持股股东
占比
Nantahala Capital Management, LLC
48.85%
Lytton (Laurence W)
6.76%
Vizirgianakis (Stavros G)
5.37%
AWM Investment Company, Inc.
4.71%
The Vanguard Group, Inc.
1.68%
其他
32.63%
股东类型
持股股东
占比
Hedge Fund
49.59%
Individual Investor
16.56%
Investment Advisor/Hedge Fund
5.20%
Investment Advisor
2.37%
Research Firm
0.04%
其他
26.23%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
58
80.07M
57.19%
-75.11M
2025Q2
66
93.42M
67.06%
-16.04M
2025Q1
66
107.33M
77.15%
-2.25M
2024Q4
65
107.45M
77.30%
-1.32M
2024Q3
60
109.08M
78.63%
+8.43M
2024Q2
61
99.68M
76.50%
-1.69M
2024Q1
63
100.56M
77.45%
+777.79K
2023Q4
59
100.17M
77.23%
+1.05M
2023Q3
55
100.31M
77.56%
+9.94M
2023Q2
49
90.55M
83.28%
+1.27M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Nantahala Capital Management, LLC
68.39M
48.85%
--
--
Aug 01, 2025
Lytton (Laurence W)
9.46M
6.76%
+9.46M
--
Apr 15, 2025
Vizirgianakis (Stavros G)
6.96M
4.97%
+748.65K
+12.05%
Sep 09, 2025
AWM Investment Company, Inc.
6.60M
4.71%
+6.60M
--
Jun 30, 2025
The Vanguard Group, Inc.
2.25M
1.61%
--
--
Jun 30, 2025
Browne (Sean E.)
1.54M
1.1%
+43.55K
+2.90%
Sep 09, 2025
Beeson (Jonn R.)
1.37M
0.98%
+162.16K
+13.37%
Sep 09, 2025
Bakewell (John K)
755.89K
0.54%
+162.16K
+27.31%
Sep 09, 2025
Renaissance Technologies LLC
650.71K
0.46%
-60.50K
-8.51%
Jun 30, 2025
Neils (Scott C)
311.72K
0.22%
+111.54K
+55.72%
Sep 09, 2025
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Xtant Medical Holdings Inc的前五大股东是谁?

Xtant Medical Holdings Inc 的前五大股东如下:
Nantahala Capital Management, LLC持有股份:68.39M,占总股份比例:48.85%。
Lytton (Laurence W)持有股份:9.46M,占总股份比例:6.76%。
Vizirgianakis (Stavros G)持有股份:6.96M,占总股份比例:4.97%。
AWM Investment Company, Inc.持有股份:6.60M,占总股份比例:4.71%。
The Vanguard Group, Inc.持有股份:2.25M,占总股份比例:1.61%。

Xtant Medical Holdings Inc的前三大股东类型是什么?

Xtant Medical Holdings Inc 的前三大股东类型分别是:
Nantahala Capital Management, LLC
Lytton (Laurence W)
Vizirgianakis (Stavros G)

有多少机构持有Xtant Medical Holdings Inc(XTNT)的股份?

截至2025Q3,共有58家机构持有Xtant Medical Holdings Inc的股份,合计持有的股份价值约为80.07M,占公司总股份的57.19%。与2025Q2相比,机构持股有所增加,增幅为-9.87%。

哪个业务部门对Xtant Medical Holdings Inc的收入贡献最大?

在FY2025Q2,Orthobiologics业务部门对Xtant Medical Holdings Inc的收入贡献最大,创收19.37M,占总收入的54.70%。
KeyAI